title: Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
abstract: OBJECTIVE
  To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC).
  
  
  METHODS
  Thirty-two patients with extrahepatic metastasis of HCC after local treatment were prospectively enrolled. The CapeOx regimen consisted of capecitabine 1000 mg/m(2) taken orally twice daily on days 1-14, and oxaliplatin was administered at a total dose of 100 mg/m(2) on day 1. The treatment was repeated every 3 wk until disease progression or unaccetablle toxicity. Efficacy and safety were assessable for all enrolled patients. The primary objective of this study was to assess the overall response rate. The secondary objectives were to evaluate the overall survival (OS), the time to tumor progression (TTP) and the toxicity profile of the combined strategy. TTP and OS were assessed by the Kaplan-Meier method and differences between the curves were analyzed using the log-rank test. The statistical software SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, United States) was used for statistical analysis. All P values were 2-tailed, with statistical significance defined by P ≤ 0.05.
  
  
  RESULTS
  Thirty-two patients were assessable for efficacy and toxicity. The median follow-up duration was 15 mo (range, 12-20 mo). At the cut-off date of March 31, 2012, 27 patients died due to tumor progression and one patient died of myocardial infarction. Four patients were still alive (three patients with disease progression). OR was 21.9% (n = 7), the stabilization rate was 40.6% (n = 13), and the disease control rate was 62.5%. The responses lasted from 4 to 19 mo (median, 6 mo). Median TTP was 4.2 mo (95%CI: 2.5-7.4), and the median OS time was 9.2 mo (95%CI: 6.5-17.8). The 1-year survival rate was 43.6% (95%CI: 29.0-66.0). In a multivariate analysis, OS was significantly longer in patients with a Child-Pugh class A compared with class B patients (P = 0.014), with a median OS of 10.1 mo vs 5.4 mo, and there were trends towards longer OS (P = 0.065) in patients without portal vein tumor thrombosis. There were no significant effects of age, gender, performance status, cirrhosis, metastatic sites, and level of alpha fetoprotein (AFP) or hepatitis B virus-DNA on OS. Among the 22 patients with elevated AFP levels at baseline (≥ 400 ng/mL), the level fell by more than 50% during treatment in 6 patients (27.3%). The most frequent treatment-related grade 3 to 4 toxicities included leucopenia/neutropenia, transient elevation of aminotransferases, hand-foot syndrome and fatigue.
  
  
  CONCLUSIONS
  CapeOx showed modest anti-tumor activity in metastatic HCC. However, the manageable toxicity profile and the encouraging disease control rate deserve further study for these patients.
authors.affiliation: Department of Hepato-Biliary and Pancreatic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200240, China. hlshli@yeah.net
authors.forename: Sheng-Li
authors.initials: SL
authors.lastname: He
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Xian-Jun
authors.initials: XJ
authors.lastname: Sun
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Zhu
authors.forename: Lu-Ming
authors.initials: LM
authors.lastname: Liu
authors.forename: Jing-Cheng
authors.initials: JC
authors.lastname: Dong
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011446:Prospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
keywords: Capecitabine; Extrahepatic metastasis; Hepatocellular carcinoma; Local treatments; Oxaliplatin
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Clin Cancer Res. 1999 Jul;5(7):1696-702
references.pmid: 10430071
references.citation: J Gastroenterol Hepatol. 2009 May;24(5):800-5
references.pmid: 19175825
references.citation: Med Oncol. 2012 Dec;29(4):2793-9
references.pmid: 22427209
references.citation: Hepatology. 1999 Jan;29(1):62-7
references.pmid: 9862851
references.citation: J Surg Oncol. 2010 Mar 1;101(3):239-43
references.pmid: 20127898
references.citation: Aliment Pharmacol Ther. 2011 Nov;34(10):1193-201
references.pmid: 21958438
references.citation: Ann Oncol. 2006 Jul;17(7):1176-7
references.pmid: 16798837
references.citation: Cancer. 2007 Apr 1;109(7):1384-90
references.pmid: 17330837
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Hepatogastroenterology. 2012 Oct;59(119):2264-8
references.pmid: 22389294
references.citation: Clin Colorectal Cancer. 2005 Nov;5(4):279-82
references.pmid: 16356306
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Ann Oncol. 2009 Aug;20(8):1402-7
references.pmid: 19502532
references.citation: Ann Oncol. 2004 Nov;15(11):1661-6
references.pmid: 15520068
references.citation: Gastrointest Cancer Res. 2011 May;4(3):78-83
references.pmid: 22043322
references.citation: J Clin Oncol. 2004 Jan 1;22(1):23-30
references.pmid: 14665611
references.citation: Br J Cancer. 2007 Oct 8;97(7):862-7
references.pmid: 17876335
references.citation: Cancer. 2011 Jul 15;117(14):3187-92
references.pmid: 21264839
references.citation: Anticancer Res. 2011 Oct;31(10):3493-6
references.pmid: 21965767
references.citation: Br J Cancer. 2006 Apr 10;94(7):964-8
references.pmid: 16552436
references.citation: Onkologie. 2006 Jun;29(6):273-5
references.pmid: 16783902
references.citation: Invest New Drugs. 2012 Feb;30(1):376-81
references.pmid: 20798975
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Hepatology. 2013 Mar;57(3):1046-54
references.pmid: 23299720
references.citation: Ann Oncol. 2013 Feb;24(2):406-411
references.pmid: 23041587
references.citation: Cancer. 2000 May 1;88(9):1986-91
references.pmid: 10813709
references.citation: Oncology. 2004;66(4):253-9
references.pmid: 15218291
references.citation: Cancer. 2004 Aug 1;101(3):578-86
references.pmid: 15274071
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1106-10
references.pmid: 20300004
references.citation: Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1187-95
references.pmid: 19409725
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4293-300
references.pmid: 16908937
references.citation: Neoplasma. 2008;55(1):65-70
references.pmid: 18190244
references.citation: Chem Commun (Camb). 2012 May 25;48(42):5139-41
references.pmid: 22517491